Monday Premium Alert: This $2 Profile (NYSE: PTN) Has a Staggering $70 Analyst Price Target

This $2 Stock Has Several Analysts Predicting 2,500%+ Upside Potential Now Turn Your Complete Attention to (NYSE: PTN) Your New Premium Biotech Breakout Alert For Monday! According to H.C. Wainwright, Palatin Technologies (NYSE: PTN) has 2,945.84% upside potential, based on the analysts’ average price target. Hi 10XProTrader Member, This is Kevin Vander with “10XProTrader” delivering you your new premium alert for Monday 8/7 - trading session is Palatin Technologies Inc. (NYSE: PTN). Special Attention Needed: Your new Premium alert has a staggering 2,945.84% upside according to one Wall Street analyst. It has been a long time since I have discovered such an incredible stock like (PTN) that has such an enormous upside potential according to analyst. The Company has several bullish catalysts in the pipeline and is on the verge of potentially Disrupting a USD $566 Bln. Biopharmaceutical Space with focuses on the research and development of targeted receptor therapeutics for a wide range of diseases and ailments. Additionally, what draws me to (NYSE: PTN) right now is Multiple Analysts are Bullish and it has received a Buy rating from H.C. Wainwright analyst Joseph Pantginis. In his assessment, Pantginis emphasizes the undervaluation of the stock and maintains a price target of $70/share. Bullish Catalyst - H.C. Wainwright Reiterated a Buy rating on Palatin Technologies with a price target of $70.00. Initiating with Buy Rating and $70.00 PT According to H.C. Wainwright, Palatin Technologies (NYSE: PTN) has 2,945.84% upside potential, based on the analysts’ average price target. Bullish Catalyst - Ladenburg Thalmann Issued Buy rating on Palatin Technologies (NYSE: PTN) with a price target of $50.00. Initiating with Buy Rating and $50.00 PT According to Ladenburg Thalmann, Palatin Technologies (NYSE: P TN) has 2,451.02% upside potential, based on the analysts’ average price target. Palatin Technologies (NYSE: PTN) is an overlooked micro-cap which has exceptional future potential in their FDA approved drug, Vyleesi. Vyleesi is their FDA-approved commercial product for pre-menopausal women with hypoactive sexual desire disorder, or HSDD. The goal of the Vyleesi program is to demonstrate commercial product value in the marketplace with an objective of licensing the U.S. rights to a committed women’s health care company. Demonstrated Leader In The Discovery And Development Of Melanocortin Agonist Treatments They have only just started tapping into the utility of melanocortin pathways in treating patients after establishing themselves with Vyleesi® (bremelanotide injection) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, as the first FDA-approved melanocortin agent. They are focused on amplifying its commercial platform in North America, supporting commercialization partners globally, and subsequently re-licensing to committed partners in the U.S. and worldwide. Their development arm builds on their proven success in bringing a melanocortin therapeutic from the lab to market by using their experience to propel their programs in ocular and autoimmune diseases through their clinical pipeline. Palatin Technologies is seeking licensing deals with additional markets for Vyleesi, which would unlock massive value for shareholders. In addition, their dry-eye disease drug is another upcoming bullish catalyst. Pioneering A New Treatment Paradigm For Ocular Diseases The need for innovative treatments for ocular indications remains unmet. Specifically, dry eye disease (DED) is a chronic, painful, and debilitating inflammatory eye condition that causes irritation, redness, discharge, and blurred vision. Over 20 million people in the U.S. are estimated to be living with DED. Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye. Melanocortin agonists provide potential advantages over current options to better meet the needs of patients and clinicians by directly addressing harmful inflammation, resulting in rapid, global improvement of affected tissues. Our PL9643 ophthalmic solution (topical eye drops) is advancing into late-stage clinical studies. Our Phase 2 study demonstrated improvements in both the signs and symptoms of DED after just 2 weeks of treatment, with no safety signals and excellent tolerability. Additional melanocortin receptor agonists are under investigation to resolve other inflammatory ocular diseases, including non-infectious uveitis, diabetic retinopathy, and diabetic macular edema. Advancing A Novel Approach To Treating Autoimmune Diseases There’s incredible potential to address the underlying inflammation in autoimmune diseases that physicians commonly treat with broad immunosuppressants that increase the risk of complications. The presence of high MCR1 levels in the gut makes ulcerative colitis (UC) a target for melanocortin receptor agonist therapy. This will benefit the nearly 1 million people in the U.S. who suffer from an autoimmune disease that manifests as chronic inflammation of the colon. Our oral MCR1 agonist (PL8177) was developed to resolve inflammation directly in the colon, avoiding broad immunosuppression and adverse effects with our potent, selective compound. This delayed-release, oral formulation is designed to deliver drug to diseased bowel, maximizing local treatment while avoiding systemic adverse effects. Two Phase 1 studies have produced promising results. The first demonstrated significant safety and tolerability of PL8177; the second highlighted the value of an oral, delayed-release polymer formulation that can achieve local release without systemic absorption. We have scheduled a Phase 2 trial in UC for the second quarter of 2022. Look No Further, This Under-The-Radar Stock Has Two Jaw Dropping Analyst Price Targets! It Does Not Get Better Than This! According to H.C. Wainwright, Palatin Technologies (NYSE: PTN) has 2,945.84% upside potential, based on the analysts’ average price target. According to Ladenburg Thalmann, Palatin Technologies (NYSE: P TN) has 2,451.02% upside potential, based on the analysts’ average price target. Palatin Technologies is a biopharmaceutical company specializing in developing peptide therapeutics for the treatment of diseases with significant unmet medical and commercial needs. Palatin's goal is to be a pioneer in a relatively new class of drugs, the melanocortin agonists, which until recent years had no drugs approved for human use. Their primary product and main success in this field is Vyleesi, the trade name for Bremelanotide, which is the first FDA-approved melanocortin agent for the treatment of HSDD (hypoactive sexual desire disorder) in premenopausal women. Since the approval, the stock has been in no man's land, and the future potential in Vyleesi has remained untapped, as some speculated that while FDA approved, the drug would ultimately become a failure. It is quite a feat that the company has the world's first, and only, FDA approved aphrodisiac. Often referred to as “Female Viagra,” Vyleesi is a very misunderstood drug and needs clarification against past competition, such as Addyi, which was developed by Sprout Pharmaceuticals. The main difference between these drugs is the interaction with alcohol in the body – Addyi was recommended to not be taken if accompanied by multiple drinks, whereas Vyleesi does not interact with alcohol at all. Another misunderstanding is that the drug only works for women. Studies have shown that the drug also has an effect in men. There is potential that Vyleesi could be prescribed by a physician for off-label uses in men for erectile dysfunction, not only for those who have hypoactive sexual desire disorder or cannot take other drugs which may interfere with other medications and alcohol. Sprout Pharmaceuticals was acquired by Valeant in 2015 for USD $1 Bln, but was later re-acquired by CEO Cindy Eckert and shareholders in a truly unprecedented move. This acquisition, and subsequent reversal, shows the potential for a company like Palatin, whose stock remains undervalued and largely unappreciated by the investment community. The past acquisition of Sprout Pharmaceuticals shows that there is quite a bit of value waiting to be unlocked in this class of drugs, to the tune of several hundred million, if not a billion dollars. There is a possibility that Palatin could become a potential prime acquisition target if it appeared on the radar of a larger pharmaceutical company. The question is, what entity is most likely to be this larger player, and what price would be fair for an acquisition? The few analysts who cover this company seem to be in agreement that there is significant upside for the shares, with price targets now ranging from $50.00 to as high as $70.00. I am urging all of our 10X members to conduct your own research, add PTN to the top of your watch list right now, and be ready Monday morning at the opening bell! 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid advertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $35,000 USD to disseminate this communication. We have never received stock in PTN, nor have we traded it. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. To view our disclosures and disc∙laimers in full, or for more information about this advertisement, visit [(. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.